PEDIATRICS Vol. 101 No. 6 June 1998, pp. 1013-1019
Incidence and Prevalence of Neutralizing Antibodies to the Common Adenoviruses in Children With Cystic Fibrosis: Implication for Gene Therapy With Adenovirus Vectors
Received Jun 26, 1997; accepted Nov 7, 1997.
,
, and
From the Departments of * Microbiology and Immunology, and
Pediatrics, Baylor College of Medicine, Houston, Texas; the
§ Department of Pediatrics, Children's Hospital Medical Center,
Seattle, Washington; and the Department of Pediatrics, Children's
Hospital at Columbus, Columbus, Ohio.
Objective. Defining the infection rate and prevalence of the common adenoviruses (Ads) in cystic fibrosis (CF) children may aid in formulation of strategies for gene therapy with Ad vectors. We undertook this study to determine the incidence and prevalence of infection with the common Ads in children with CF.
Methodology. Thirty newly diagnosed CF children mean age 1.1 years (Group 1), 48 CF children mean age 4.6 years (Group 2), and 47 mothers of CF children (Group 3) were followed for a mean of 13 months. Group 4 consisted of 33 adult volunteers seen once. Throat and stool specimens for virus culture, and blood samples were obtained every 3 months from CF children in Group 1. Blood samples from CF children (Group 2) and their mothers (Group 3) were obtained every 6 months, and once from adults in Group 4. Neutralizing antibody to Ad serotypes 1 through 7 (Ad 1 to Ad 7) was evaluated with a microneutralization assay.
Results. Five (16.7%) CF children in Group 1 were culture-positive for an Ad; 4 of these CF children developed a fourfold or greater rise in antibody titer. Ad 3 infection occurred frequently based on serology; seronegative (<3.5 log 2) CF children had a higher infection rate compared with seropositive CF children (7/11 vs 1/34). The prevalence of neutralizing antibodies in CF children in order of decreasing frequency was 91.1% to Ad 3, 37.5% to Ad 2, 27.1% to Ad 1, 26.1% to Ad 7, 16.7% to Ad 5, 8.5% to Ad 4, and 2.0% to Ad 6. The neutralizing antibody titers in seropositive CF children were comparable to those in adults except to Ad 3, which was significantly greater in mothers of CF children.
Conclusions. CF children had a normal antibody response after Ad infection, preexisting antibody may protect against reinfection and antibody prevalence was low to the common Ads.
Key words: adenovirus, CF children, neutralizing antibodies to adenoviruses.
CiteULike 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
This article has been cited by other articles:
|
|
 |
|
  T. W. Geisbert, J. B. Geisbert, A. Leung, K. M. Daddario-DiCaprio, L. E. Hensley, A. Grolla, and H. Feldmann Single-Injection Vaccine Protects Nonhuman Primates against Infection with Marburg Virus and Three Species of Ebola Virus J. Virol., July 15, 2009; 83(14): 7296 - 7304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. C. Nwanegbo, E. G. Romanowski, Y. J. Gordon, and A. Gambotto Efficacy of Topical Immunoglobulins against Experimental Adenoviral Ocular Infection Invest. Ophthalmol. Vis. Sci., September 1, 2007; 48(9): 4171 - 4176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Appaiahgari, R. M. Pandey, and S. Vrati Seroprevalence of Neutralizing Antibodies to Adenovirus Type 5 among Children in India: Implications for Recombinant Adenovirus-Based Vaccines Clin. Vaccine Immunol., August 1, 2007; 14(8): 1053 - 1055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hamilton, D. E. Brough, D. McVey, J. T. Bruder, C. R. King, and L. L. Wei Repeated Administration of Adenovector in the Eye Results in Efficient Gene Delivery Invest. Ophthalmol. Vis. Sci., January 1, 2006; 47(1): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A Lee, N. H. Kim, S. J. Kim, E. H. Choi, and H. J. Lee Rapid Identification of Human Adenovirus Types 3 and 7 from Respiratory Specimens via Multiplex Type-Specific PCR J. Clin. Microbiol., November 1, 2005; 43(11): 5509 - 5514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hashimoto, J. L. Boyer, N. R. Hackett, J. M. Wilson, and R. G. Crystal Induction of Protective Immunity to Anthrax Lethal Toxin with a Nonhuman Primate Adenovirus-Based Vaccine in the Presence of Preexisting Anti-Human Adenovirus Immunity Infect. Immun., October 1, 2005; 73(10): 6885 - 6891. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Varghese, Y. Mikyas, P. L. Stewart, and R. Ralston Postentry Neutralization of Adenovirus Type 5 by an Antihexon Antibody J. Virol., November 15, 2004; 78(22): 12320 - 12332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Tominaga, S Kuriyama, H Yoshiji, A Deguchi, Y Kita, F Funakoshi, T Masaki, K Kurokohchi, N Uchida, T Tsujimoto, et al. Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies Gut, August 1, 2004; 53(8): 1167 - 1173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Sprangers, W. Lakhai, W. Koudstaal, M. Verhoeven, B. F. Koel, R. Vogels, J. Goudsmit, M. J. E. Havenga, and S. Kostense Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors J. Clin. Microbiol., November 1, 2003; 41(11): 5046 - 5052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-J. Kim, J.-Y. Hong, H.-J. Lee, S.-H. Shin, Y.-K. Kim, T. Inada, M. Hashido, and P. A. Piedra Genome Type Analysis of Adenovirus Types 3 and 7 Isolated during Successive Outbreaks of Lower Respiratory Tract Infections in Children J. Clin. Microbiol., October 1, 2003; 41(10): 4594 - 4599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Fitzgerald, G.-P. Gao, A. Reyes-Sandoval, G. N. Pavlakis, Z. Q. Xiang, A. P. Wlazlo, W. Giles-Davis, J. M. Wilson, and H. C. J. Ertl A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag J. Immunol., February 1, 2003; 170(3): 1416 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gaden, L. Franqueville, S. S. Hong, V. Legrand, C. Figarella, and P. Boulanger Mechanism of Restriction of Normal and Cystic Fibrosis Transmembrane Conductance Regulator-Deficient Human Tracheal Gland Cells to Adenovirus Infection and Ad-Mediated Gene Transfer Am. J. Respir. Cell Mol. Biol., November 1, 2002; 27(5): 628 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Skog, Y.-F. Mei, and G. Wadell Human adenovirus serotypes 4p and 11p are efficiently expressed in cell lines of neural tumour origin J. Gen. Virol., June 1, 2002; 83(6): 1299 - 1309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Ogra, H. Faden, and R. C. Welliver Vaccination Strategies for Mucosal Immune Responses Clin. Microbiol. Rev., April 1, 2001; 14(2): 430 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Angella, M. B. Sherwood, L. Balasubramanian, J. W. Doyle, M. F. Smith, G. van Setten, M. Goldstein, and G. S. Schultz Enhanced Short-Term Plasmid Transfection of Filtration Surgery Tissues Invest. Ophthalmol. Vis. Sci., December 1, 2000; 41(13): 4158 - 4162. [Abstract] [Full Text]
|
|
|
|
|
|
E. J. Kremer, S. Boutin, M. Chillon, and O. Danos Canine Adenovirus Vectors: an Alternative for Adenovirus-Mediated Gene Transfer J. Virol., January 1, 2000; 74(1): 505 - 512. [Abstract] [Full Text]
|
|
|
|
 |
|
 N. Morral, W. O'Neal, K. Rice, M. Leland, J. Kaplan, P. A. Piedra, H. Zhou, R. J. Parks, R. Velji, E. Aguilar-Cordova, et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons PNAS, October 26, 1999; 96(22): 12816 - 12821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B.-G. Harvey, N. R. Hackett, T. El-Sawy, T. K. Rosengart, E. A. Hirschowitz, M. D. Lieberman, M. L. Lesser, and R. G. Crystal Variability of Human Systemic Humoral Immune Responses to Adenovirus Gene Transfer Vectors Administered to Different Organs J. Virol., August 1, 1999; 73(8): 6729 - 6742. [Abstract] [Full Text]
|
|
|
|
|
|
D. Maione, C. D. Rocca, P. Giannetti, R. D'Arrigo, L. Liberatoscioli, L. L. Franlin, V. Sandig, G. Ciliberto, N. La Monica, and R. Savino An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus PNAS, May 22, 2001; 98(11): 5986 - 5991. [Abstract] [Full Text] [PDF]
|
|
